Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations

INTRODUCTION: Natalizumab is a biologic drug for relapsing-remitting multiple sclerosis that may induce the generation of anti-drug antibodies in some patients. Anti-natalizumab antibodies (ANA) increase the risk of adverse events and reduce efficacy, being useful biomarkers for monitoring treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciano-Petersen, Nicolás Lundahl, Aliaga-Gaspar, Pablo, Hurtado-Guerrero, Isaac, Reyes, Virginia, Rodriguez-Bada, José Luis, Rodriguez-Traver, Eva, Brichette-Mieg, Isabel, Leyva Fernández, Laura, Serrano-Castro, Pedro, Alonso, Ana, Oliver-Martos, Begoña
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478078/
https://www.ncbi.nlm.nih.gov/pubmed/37675113
http://dx.doi.org/10.3389/fimmu.2023.1242508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478078/
https://www.ncbi.nlm.nih.gov/pubmed/37675113
http://dx.doi.org/10.3389/fimmu.2023.1242508

Ejemplares similares